You are here

Article Text

Article menu

Download PDFPDF

Endometrial cancer
2022-RA-659-ESGO The role of molecular classification in endometrial cancers with lymph nodes metastasis
Free
  1. Gabriella Schivardi1,2,
  2. Luigi Antonio de Vitis2,
  3. Caterina Fumagalli3,4,
  4. Paola Rafaniello Raviele5,6,
  5. Maria Teresa Achilarre2,
  6. Alessia Aloisi2,
  7. Annalisa Garbi2,
  8. Mariateresa Lapresa2,
  9. Gabriella Parma2,
  10. Vanna Zanagnolo2,
  11. Giovanni Damiano Aletti2,7,
  12. Elena Guerini-Rocco5,7,
  13. Andrea Mariani1,
  14. Angelo Maggioni2,
  15. Massimo Barberis5,
  16. Nicoletta Colombo2,8,
  17. Ilaria Betella2 and
  18. Francesco Multinu2
  1. 1Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN
  2. 2Department of Gynecology, European Institute of Oncology, IEO, IRCCS, Milan, Italy
  3. 3Clinical Unit of Oncogenomics, European Institute of Oncology, IEO, IRCCS, Milan, Italy
  4. 4Division of Pathology, ASST Valle Olona, Gallarate, Italy
  5. 5Department of Pathology, European Institute of Oncology, IEO, IRCCS, Milan, Italy
  6. 6Division of Pathology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
  7. 7Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
  8. 8Faculty of Medicine and Surgery, University of Milan Bicocca, Milan, Italy

Abstract

Introduction/Background The role of molecular characterization in predicting the presence of lymph nodes metastasis has not been completely clarified. The primary aims of this study were to describe the molecular characterization of endometrial cancer (EC) with lymph nodes metastasis and to assess the association between molecular classes and lymph nodal involvement.

Methodology EC patients undergoing molecular characterization at the European Institute of Oncology, Milan from April 2019 to December 2021 were retrospectively identified. All patients underwent surgical staging including sentinel lymph node biopsy or systematic lymphadenectomy. Patients with FIGO stage IV were excluded. Molecular analysis included immunohistochemistry for p53 and MMR proteins, microsatellite instability assay, and Next Generation Sequencing for POLE exonuclease domain and TP53. ECs were classified into 4 molecular classes (POLEmut, MMR deficiency [MMRd], p53 abnormality [p53abn], and non-specific molecular profile [NSMP]). Associations between molecular classes and lymph nodes metastasis were evaluated with univariate and multivariate statistical analysis.

Results In total, 317 patients meeting inclusion criteria were included. Molecular classification showed 150(47.3%) NSMP, 101(31.9%) MMRd, 38(12%) p53abn, and 28(8.8%) POLEmut. Among them, 64 (20.2%) had lymph nodes metastasis, including 29(45.3%) NSMP, 26(40.6%) MMRd, 8(12.5%) p53abn, and 1(1.6%) POLEmut. In the univariate analysis high grade(p=0.03), myometrial invasion(p<0.0001), cervical stromal invasion(p=0.0004), lymph vascular space invasion (LVSI)(p<0.0001), positive peritoneal cytology (p=0.02), and uterine serosal involvement (p=0.03) were predictors of lymph nodal metastasis, while POLEmut (vs. other risk classes) was a protective factor (p=0.02). In the multivariate analysis, myometrial invasion (p=0.0007), LVSI (p=0.0003), and peritoneal cytology (p=0.02) were independent predictors of lymph nodes metastasis, while POLEmut class showed a protective role (p=0.03).

View this table:
Abstract 2022-RA-659-ESGO Table 1

Conclusion POLEmut class is associated with a low rate of lymph node involvement and has an independent protective role on lymph nodal metastasis. If confirmed by future studies, these results could be potentially used to tailor surgical staging.

https://doi.org/10.1136/ijgc-2022-ESGO.225

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.